UCLA researchers in the Division of Cardiology at the Geffen School of Medicine have developed novel devices and methods for allowing entirely intravascular access to the left ventricle, thereby precluding access via the apex of the heart percutaneously or by surgery.
Many cardiac and vascular interventions, such as transapical aortic valve replacement, mitral valve repair and replacement, and retrograde aortic root endograft procedures require safe and reliable direct percutaneous access and closure of access to the left ventricle. Direct left ventricular (LV) access involving trans-atrial or trans-septal surgery risks injury to critical structures, including the ventricular septum or coronary arteries, and requires immediate recognition of procedural complications, including pericardial tamponade or hemothorax.
Researchers at UCLA have developed a novel device that allows access of therapeutic and diagnostic devices into the left ventricle from the venous side. This device will create a platform for accessing left sided structures including the aortic and mitral valves.
Left ventricular access in the field of cardiac electrophysiology and cardiac surgery
Country | Type | Number | Dated | Case |
United States Of America | Issued Patent | 10426515 | 10/01/2019 | 2008-788 |
Cardiovascular, left ventricle access, medical device